Abstract
Treating malignant tumor through the induction of cell differentiation has been an attractive concept, but clinical development of differentiation-inducing agents to treat malignant tumor, especially for solid tumors has been limited to date. Nerve growth factor, all trans retinoic acid, dimethyl sulfoxide, active form vitamin D3, peroxisome proliferatoractivated receptorg, 12-0-tetradecanoylphorbol 13-acetate, hexamethylene-bis-acetamide, transforming growth factor-β, butyric acid, cAMP, and vesnarinone are known to have a differentiation-inducing capability on solid tumors in vitro and/or in vivo. Moreover some of the differentiation-inducing agents have been used for treating patients with solid tumor, but the therapeutic effect of the differentiation-inducing agents on solid tumor is not strong when compared with that of conventional chemotherapeutic agents. However, because most of the differentiation-inducing agents can potentiate the effect of conventional chemotherapy or radiation therapy, combination of differentiation-inducing therapy with conventional chemotherapy or radiation therapy might be used as a second- or third-line therapy in patients with advanced cancer. Furthermore, analysis of the molecular mechanisms of the tumor differentiation therapy might provide selective and targeted molecules for novel cancer therapy.
Keywords: Differentiation, solid tumor, salivary gland tumor, tumor dormancy, vesnarinone, TSC-22
Current Pharmaceutical Design
Title: Differentiation-Inducing Therapy for Solid Tumors
Volume: 12 Issue: 3
Author(s): Hitoshi Kawamata, Masatsugu Tachibana, Takahiro Fujimori and Yutaka Imai
Affiliation:
Keywords: Differentiation, solid tumor, salivary gland tumor, tumor dormancy, vesnarinone, TSC-22
Abstract: Treating malignant tumor through the induction of cell differentiation has been an attractive concept, but clinical development of differentiation-inducing agents to treat malignant tumor, especially for solid tumors has been limited to date. Nerve growth factor, all trans retinoic acid, dimethyl sulfoxide, active form vitamin D3, peroxisome proliferatoractivated receptorg, 12-0-tetradecanoylphorbol 13-acetate, hexamethylene-bis-acetamide, transforming growth factor-β, butyric acid, cAMP, and vesnarinone are known to have a differentiation-inducing capability on solid tumors in vitro and/or in vivo. Moreover some of the differentiation-inducing agents have been used for treating patients with solid tumor, but the therapeutic effect of the differentiation-inducing agents on solid tumor is not strong when compared with that of conventional chemotherapeutic agents. However, because most of the differentiation-inducing agents can potentiate the effect of conventional chemotherapy or radiation therapy, combination of differentiation-inducing therapy with conventional chemotherapy or radiation therapy might be used as a second- or third-line therapy in patients with advanced cancer. Furthermore, analysis of the molecular mechanisms of the tumor differentiation therapy might provide selective and targeted molecules for novel cancer therapy.
Export Options
About this article
Cite this article as:
Kawamata Hitoshi, Tachibana Masatsugu, Fujimori Takahiro and Imai Yutaka, Differentiation-Inducing Therapy for Solid Tumors, Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201947
DOI https://dx.doi.org/10.2174/138161206775201947 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets Ovulation, Implantation and Placentation in Females with Obesity and Metabolic Disorders: Life in the Balance
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry MiR-29 Targets PUMA to Suppress Oxygen and Glucose Deprivation/Reperfusion (OGD/R)-induced Cell Death in Hippocampal Neurons
Current Neurovascular Research A Novel Assay Platform for the Detection of Translation Modulators of Spermidine/ Spermine Acetyltransferase
Current Pharmaceutical Design Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Congestive Heart Failure: Pharmacological Agents and the Potential of BType Natriuretic Peptide
Current Medicinal Chemistry The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics Sulfonated Carbon/Silica Composites: Highly Efficient Heterogeneous Catalysts for the One-Pot Synthesis of Hantzsch 1,4-dihydropyridines, 2,4,5-trisubstituted Imidazoles and 2-arylbenzimidazoles
Current Catalysis Steroidal Conjugates and Their Pharmacological Applications
Current Medicinal Chemistry Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity
Current Alzheimer Research Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine A Review of the Therapeutic Benefits of Moringa oleifera in Controlling High Blood Pressure (Hypertension)
Current Traditional Medicine Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets